Roivant Sciences Ltd.ROIV
NasdaqGS•Healthcare•Biotechnology
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Roivant Sciences Ltd. (ROIV) reported trailing twelve months revenue of $8.26M as of March 2026, a 71.6% decline year-over-year. Quarterly revenue reached $2.52M, reflecting a contraction in sales.
Roivant Sciences Ltd. reported a TTM net loss of $299.77M, with quarterly EBITDA of $417.49M. The operating margin expanded from 674.8% to 16477.8%, suggesting improving cost efficiency and pricing discipline.
The spread between operating margin (16477.8%) and net margin (12023.6%) indicates significant non-operating expenses or interest burden. Net margin has improved from 521.8% a year ago, signaling stronger bottom-line efficiency.
ROIV trades at a P/S of 2293.7x. The price-to-book ratio of 4.2x reflects a moderate premium to book value.
The company reported negative free cash flow of $-165.08M, indicating cash consumption over the period. The balance sheet shows $5.71B in total assets with no in long-term debt against $4.53B in stockholders equity. Data based on the most recent quarterly reports.
Competitive analysis based on 19 quarters of fundamental data
Operating margins are under pressure, averaging -5416.6%. The business may lack pricing power or face rising costs.'
ROE averages 28.1% but has fluctuated — the competitive advantage may be cyclical or emerging.
Only 0 of the last 8 quarters had positive FCF — the business may require external capital to sustain operations.
Revenue has been flat or declining over recent quarters, which may indicate eroding demand or competitive pressure.
Data-driven red flags and warnings across 19 quarters
The company posted negative operating margins in recent quarters — core operations are unprofitable.
Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.
Limited debt-to-equity data available.
TTM revenue has contracted 118.2% — significant decline indicating deteriorating demand.
The last 8 consecutive quarters had negative FCF — the company is burning cash and may need external funding.
Shares decreased 2.5% — net buybacks are reducing shares outstanding and boosting per-share value.
Quarterly standardized metrics.
Stock price and market valuation
Revenue and earnings growth across quarters
Assets, cash, debt, and leverage
Price multiples and return ratios
Operating efficiency and return metrics
Free cash flow, earnings quality, and capital allocation